Versant Capital Management, Inc Pacira Bio Sciences, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 1,178 shares of PCRX stock, worth $27,294. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,178
Previous 1,052
11.98%
Holding current value
$27,294
Previous $26,000
7.69%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding PCRX
# of Institutions
255Shares Held
51.1MCall Options Held
157KPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$186 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.24MShares$121 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$52.5 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.24MShares$51.9 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.05MShares$47.5 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.06B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...